A cost-effectiveness analysis of RefluxStop against relevant therapeutic alternatives for chronic gastroesophageal reflux disease in Sweden

Sam Harper,Muralikrishnan Kartha,Stuart Mealing,Lars Lundell
DOI: https://doi.org/10.1080/14737167.2024.2417774
2024-10-22
Expert Review of Pharmacoeconomics & Outcomes Research
Abstract:Introduction The standard treatment for gastroesophageal reflux disease (GERD) is proton pump inhibitors (PPIs). In selected cases, Nissen fundoplication is offered as a surgical treatment option, but alternative endoscopic and minimally invasive surgical alternatives are emerging. RefluxStop is a new technology for the treatment of GERD.
pharmacology & pharmacy,health care sciences & services,health policy & services
What problem does this paper attempt to address?